Musu Yuan, Kaitian Jin, Hanying Yan, Amelia Schroeder, Chunyu Luo, Sicong Yao, Bernhard Domoulin, Jonathan Levinsohn, Tianhao Luo, Jean R. Clemenceau, Inyeop Jang, Minji Kim, Yunhe Liu, Minghua Deng, Emma E. Furth, Parker Wilson, Anupma Nayak, Idania Lubo, Luisa Maren Solis Soto, Linghua Wang, Jeong Hwan Park, Katalin Susztak, Tae Hyun Hwang, Mingyao Li Designing Smart Spatial Omics Experiments with S2Omics , bioRxiv [Preprint]; Accepted in Nature Cell Biology: 2025
DeMichele A, Clark A, Shea E, Bayne L, Sterner C, Rohn K, Eberle-Dwyer S, Pan T-C, Nivar I, Chen Y, Wileyto EP, Berry L, DeLuca S, Savage J, Makhlin I, Pant D, Egunsola A, Mears N, Goodspeed B, Chislock E, Graves J, Wang J, Shih N, Belka G, Berry D, Nayak A, Feldman M, Martin H, Chodosh L. Targeting Dormant Tumor Cells to Prevent Recurrent Breast Cancer: a randomized phase 2 trial. , Nature Medicine: 2025
Griffin B. Spychalski1, Andrew A. Lin, Stephanie J. Yang, Hanfei Shen, Jean Rosario, Kyle Tien, Kate French, Miriyam Ghali, Stephanie Yee, Melinda Yin, Michael D. Feldman, Emily F. Conant, Susan P. Weinstein, Erica L. Carpenter, David Issadore, Anupma Nayak miRNA Panel from HER2+ and CD24+ Plasma Extracellular Vesicle Subpopulations as Biomarkers of Early-stage Breast Cancer , Breast Cancer Res., 27(1): 2025,90
Tondi Resta I, Nelson ND, Toorens E, Bleiweiss IJ, Nayak A. Mucinous Cystadenocarcinomas of the Breast Exhibit Heterogeneous Genomic Profile as Triple Negative Breast Cancer, Harbor Alterations in PIK3CA, PTEN, AKT1, and GNAS Genes, and May Not Be Indolent. , Int J Surg Pathol. , 33(7): 2025,1583-1592
Narasimhamurthy M, Le A, Boruah N, Moses R, Kelly G, Bleiweiss I, Maxwell KN, Nayak A. Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome. , Am J Surg Pathol., 49(3): 2025,195-205
Kaitlin Demarest, Arravinth Anantharajah, Kara N. Maxwell1, Mersedeh Rohanizadegan, Angela Bradbury, Katherine L Nathanson, Susan Domchek, Anupma Nayak, Payal D. Shah Pathogenic Germline Variants in Patients with Metaplastic Breast Cancer , JAMA Network Open
, 8(2): 2025
Young AJ, Pantel AR, Kiani M, Doot RK, Bagheri S, Pryma DA, Farwell MD, Li S, Lee H, Schubert EK, Secreto A, Zuckerman SP, Nayak A, Choi H, Carlin S, DeMichele A, Mankoff DA, Zhou R, Mach RH, McDonald ES. Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer. , J Nucl Med. , 65((12)): 2024,1862-68
Tchou J, Gottipati S, Goldbach M, Baxter M, Venters S, Chen Y, Gonzalves D, Ahmad Z, Nayak A, Mukhtar R, Boughey J. Change in Biomarker Profile after neoadjuvant chemotherapy is prognostic and is especially common in patients with HER2+ breast cancer. , Ann Surg Oncol., 31(12): 2024,8093-8101
Li X, Nguyen TTA, Zhang J, Nayak A, Liu Y, Duckworth LA, Zhang G, Bakkar R, Agarwal I, Hou Y, Guo H, Huang X, Wei S, Yasmeen S, Thaer K, Huang H, Zhang H, Smith GH, Turashvili G, Peng L, Liu Y, Yang W, Siziopikou KP. Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases , Am J Surg Pathol., 48(9): 2024,1146-1153
Boruah N, Hoyos D, Moses R, Hausler R, Desai H, Le AN, Good M, Kelly G, Raghavakaimal A, Tayeb M, Narasimhamurthy M, Doucette A, Gabriel P, Feldman MJ, Park J, de Rodas ML, Schalper KA, Goldfarb SB, Nayak A, Levine AJ, Greenbaum BD, Maxwell KN. Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers.
, bioRxiv [Preprint].: 2024
